The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Considering PRO assessments in multiple myeloma to capture AEs of novel therapies
Lisa Leypoldt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the limitations of standard patient-reported outcome (PRO) assessments in capturing new adverse events (AEs) of treatments like talquetamab. Dr Leypoldt emphasizes the importance of selecting the most suitable PRO assessment tool for a study’s specific needs and involving patient representatives to identify potential gaps in measurement. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Talking about talquetamab, there is one issue if you look at the patient-reported outcomes. And this is actually also true for some other new treatments like the belantamab mafodotin. Any of those treatments that have really new side effects that we do not capture with the sort of the standard PRO assessments, right? In this case, this is skin toxicities and also changes in taste and weight loss potentially, which are usually not captured by the most commonly used PRO assessment tools...
Talking about talquetamab, there is one issue if you look at the patient-reported outcomes. And this is actually also true for some other new treatments like the belantamab mafodotin. Any of those treatments that have really new side effects that we do not capture with the sort of the standard PRO assessments, right? In this case, this is skin toxicities and also changes in taste and weight loss potentially, which are usually not captured by the most commonly used PRO assessment tools. So I think it’s really important to really have a look when you design your study to which PRO assessment suits your study’s needs best and captures these results. For example the CTCAE does capture all these events because it’s really broad and for this it may be helpful actually to also talk to the patient representatives because sometimes they have an even better idea about different PRO measurements or what would be considered important to them. So that’s maybe some aspects to think about when designing future trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory role/honoraria: GSK, Sanofi, Janssen, Bristol Myers Squibb/Celgene; Research support: AbbVie, GSK (both to the institution); Travel support: Sanofi; Other (travel support, training): GSK, Sanofi, AbbVie.
